



## Immunotherapy for Combatting Genitourinary Tract Cancers

Guest Editor:

### Dr. Hyewon Lee

Department of Urology, National  
Cancer Center, 323 Ilsan-ro,  
Ilsandong-gu, Goyang-si 10408,  
Gyeonggi-do, Korea

Deadline for manuscript  
submissions:

**closed (30 September 2022)**

### Message from the Guest Editor

Dear Colleagues ,

Nowadays, the immunotherapeutic approach, such as using immune checkpoint inhibitors, has been widely applied as an alternative effective option against advanced genitourinary tract cancers that are refractory to first-line chemotherapies and targeted agents. Despite enhanced clinical efficacy and reduced side effects, more reliable predictive biomarkers, combination strategies to overcome limited efficacy and therapeutic resistance of single immunotherapy, novel innovative immune-modulatory tools should be investigated through comprehensive translational research for optimized personalized immunotherapy. In this Special Issue, high-quality original research articles, review papers, and meta-analysis papers will be invited and considered for peer-reviewed publication.

Dr. Hyewon Lee  
*Guest Editor*





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research  
Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA  
2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPLus / SciFinder*, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us

*Biomedicines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](http://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
X@Biomed\_MDPI